TScan Therapeutics, Inc. (TCRX) financial statements and ratios from SEC XBRL: revenue $10.32M (TTM), net margin -1256.8%, revenue growth -65.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $10.32M |
| Net Margin | -1256.8% |
| Revenue Growth (YoY) | -65.8% |
| EPS Growth (YoY) | -17.9% |
| FCF Growth (YoY) | -18.9% |
| Price / Book | 1.47 |
| Price / Sales | 14.24 |
| FCF Yield | -116.9% |
| Altman Z-Score | -3.70 (distress) |
| Sector P/E (Healthcare) | 21.7 |
TCRX overview · TCRX earnings · TCRX KPIs · TCRX investor relations · TCRX ownership · TCRX peers · TCRX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.